evidence/gaps
Cochrane · systematic review · CD007325

Anti‐vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion

Braithwaite, T, Nanji, AA, Lindsley, K, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library

Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 4 · 57.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Comparison

Population: participants with CRVO macular oedema of duration less than 9 months (mean < 3 months) and no prior treatment
7 questions
OutcomeEffectEvidenceStatus / GRADE
BCVA gain of 15 letters or more (
RR 2.71 [2.1, 3.49]6 studies · 937 participantsHigh
BCVA loss of 15 letters or more (
RR 0.2 [0.12, 0.34]5 studies · 766 participantsHigh
Mean change in BCVA from baseline (
MD 15.23 [11.57, 18.89]6 studies · 937 participantsModerate
Downgraded: risk of bias, imprecision, inconsistency, publication bias
Mean change from baseline in central retinal thickness (
no estimate extracted3 studies · 481 participantsModerate
Downgraded: risk of bias, imprecision, inconsistency, publication bias
Complication: iris or retinal neovascularisation (
RR 0.18 [0.09, 0.36]6 studies · 936 participantsHigh
Ocular adverse events: endophthalmitis at 6 months
no estimate extracted6 studies · 937 participantsHigh
Mean change from baseline in quality of life score (NEI VFQ‐25 instrument)
no estimate extracted3 studies · 743 participantsModerate
Downgraded: risk of bias, imprecision, inconsistency, publication bias